Abstracts tagged "fibrosis"

Abstract Number: 2926 • 2017 ACR/ARHP Annual Meeting
Fucosyltransferase-1 Mediates Macrophage Driven Myofibroblast Differentiation and TGF-β Signaling in Systemic Sclerosis and Bleomycin-Induced Fibrosis
W. Alexander Stinson¹, Ellen Cealey¹, Pei-Suen Tsou¹, Ray A. Ohara¹, Yuxuan Du², Jonatan Hervoso¹, Nicholas Lepore¹, Sarah Arwani¹, Dinesh Khanna¹, David A. Fox¹ and M. Asif Amin¹, ¹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ²Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, MI
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by dysregulated fibrosis of the skin. During fibrosis, macrophage release of transforming growth factor (TGF-β)…
Abstract Number: 774 • 2017 ACR/ARHP Annual Meeting
The αV Integrin Inhibitor Abituzumab Inhibits Myofibroblast Differentiation
Eileen Samy¹, Yin Wu¹, Georgianna Higginbotham², Roland Grenningloh² and Daigen Xu², ¹TIP Immunology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Scleroderma is a progressive fibrotic multi-organ disease characterized by the hardening and tightening of the skin and connective tissues. TGF-β1 is a potent mediator…
Abstract Number: 2929 • 2017 ACR/ARHP Annual Meeting
WNT5A Promotes Tissue Fibrosis By Wnt/PCP-Dependent Activation of Latent TGF-β
Chih-Wei Chen¹, Thuong Trinh-Minh², Neng-Yu Lin², Yun Zhang³, Florian Groeber⁴, Christian Beyer⁵, Georg Schett⁶ and Jörg Distler⁷, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Translational Center Würzburg, Fraunhofer Ins. IGB, Würzburg, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Canonical Wnt/β-catenin signaling has emerged as a core pathway of fibrosis. They role of non-canonical Wnt signaling, however, has not been systematically studied. In…
Abstract Number: 1679 • 2017 ACR/ARHP Annual Meeting
Different Cut-Offs for Renal Resistive Index Reflect Renal and Other Organ Involvement and Predict Worsening in SSc Patients
Cosimo Bruni¹, Vanessa Maestripieri², Giulia Tesei³, Marco Chiostri⁴, Serena Guiducci³, Silvia Bellando-Randone¹, Maria Boddi⁴ and Marco Matucci-Cerinic³, ¹Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ²Department of Internal Medicine, Division of Medicine for Care Complexity III, University of Florence, Florence, Italy, ³Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁴Department of Heart and Vessels, Division of Cardiology I, University of Florence, Florence, Italy
Background/Purpose: Renal Resistive Index (RRI), measured by Doppler ultrasound, reflects changes in both renal vascular and tubular-interstitial compartments and systemic vascular compliance related to age…
Abstract Number: 1688 • 2017 ACR/ARHP Annual Meeting
Stem Cell-Enriched Lipotransfer Substantially Improves Measures of Appearance and Function Due to Facial Fibrosis in Systemic Sclerosis
Aurora Almadori^1,2, Caroline Ryan², Michelle Griffin³, Esther Hansen⁴, Christopher Denton⁵ and Peter Butler^6,7, ¹Plastic Surgery, Royal Free NHS Foundation Trust London Hospital, London, United Kingdom, ²Division of Surgery and Interventional Science, UCL, London, United Kingdom, ³Division of Surgery and Interventional Sclemce, UCL, london, United Kingdom, ⁴Clinical Psychology, Plastic Surgery, Royal Free London NHS Foundation Trust Hospital, London, United Kingdom, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁶Plastic Surgery, Royal Free London NHS Foundation Trust Hospital, London, United Kingdom, ⁷Division of Surgery and Interveitional Science, UCL, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is characterised by fibrosis of the skin and underlying connective tissue structures, together with localised loss of subcutaneous fat. Oro-facial fibrosis…
Abstract Number: 1706 • 2017 ACR/ARHP Annual Meeting
Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis
Alina Soare¹, Hermina Györfy¹, Alexandru Matei¹, Clara Dees¹, Chih-Wei Chen¹, Andreas Ramming², Georg Schett³ and Jörg Distler¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: Dipeptidyl-peptidase-4 (DPP4) has been reported to identify a dermal fibroblast lineage involved in scaring and its inhibition leads to reduced scar formation. Its role…
Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Viktor Martyanov¹, Yolanda Nesbeth², Guoshuai Cai¹, Tammara A. Wood¹, Jake Reder², Scott Constantine³, Barbara White³, Robert F. Spiera⁴ and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Celdara Medical, LLC, Lebanon, NH, ³Corbus Pharmaceuticals, Inc., Norwood, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
Abstract Number: 1708 • 2017 ACR/ARHP Annual Meeting
Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
Janine Schniering¹, Martina Benesova^2,3, Matthias Brunner⁴, Carol A. Feghali-Bostwick⁵, Roger Schibli^2,3, Oliver Distler⁶, Cristina Müller^2,3 and Britta Maurer⁶, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Chemistry and Applied Biosciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland, Zurich, Switzerland, ³Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland, Villigen PSI, Switzerland, ⁴Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a life-threatening complication in SSc. In recent years, distinct genomic and molecular subtypes in SSc-ILD were identified and molecular…
Abstract Number: 1718 • 2017 ACR/ARHP Annual Meeting
The Role and Function of Monocyte-Derived Fibroblast-like Cells in Multi-Organ Fibrosis in Systemic Sclerosis
Michal Rudnik¹, Mara Stellato¹, Vincent Milleret², Przemyslaw Blyszczuk^1,3, Britta Maurer¹, Karin Klingel⁴, Joerg C. Henes⁵, Karl Sotlar⁶, Martin Ehrbar², Oliver Distler⁷ and Gabriela Kania¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Obstetrics, University Hospital Zurich, Zurich, Switzerland, ³Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland, ⁴Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁶Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Animal studies indicated bone marrow-derived cells as a source of pathological myofibroblasts in fibrosis of multiple organ including lungs, heart, skin and kidney. Monocytes…
Abstract Number: 1104 • 2016 ACR/ARHP Annual Meeting
Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy
Vishal Deshmukh¹, Timothy Seo¹, Maureen Ibanez¹, Luis Dellamary¹, Josh Stewart¹, John Hood² and Yusuf Yazici¹, ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC (formerly), San Diego, CA
Background/Purpose: Chronic tendinopathy is an inflammatory and degenerative condition caused by injuries or overuse. Current therapeutic options focus on alleviating the symptoms and pain rather…
Abstract Number: 3177 • 2016 ACR/ARHP Annual Meeting
Targeted Nuclear Imaging for the Early Detection of Lung Involvement in Systemic Sclerosis
Janine Schniering¹, Stephanie Haller², Zhongning Guo¹, Martina Benesova^2,3, Carol A. Feghali-Bostwick⁴, Roger Schibli^2,3, Oliver Distler⁵, Cristina Müller^2,3 and Britta Maurer⁵, ¹Department of Rheumatology, University Hospital Zurich, Schlieren, Switzerland, ²Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen PSI, Switzerland, ³Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland, ⁴Medicine, Medical University of South Carolina, Charleston, SC, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of systemic sclerosis (SSc)-related deaths. Since routine diagnostics such as high resolution computed tomography…
Abstract Number: 1671 • 2016 ACR/ARHP Annual Meeting
Pirfenidone Might Inhibit New Bone Formation in Spondyloarthritis: Proof of Concept Study Using Cell Culture Models
Julie Laustsen¹, Søren Lomholt¹, Pernille Andersen², Jens Kelsen³ and Tue Wenzel Kragstrup^1,4, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark, ³Department of Gastroenterology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) involves both inflammation and new bone formation in the spine. In line with this, the disease has been characterized…
Abstract Number: 3178 • 2016 ACR/ARHP Annual Meeting
Heart Dysfunction in Systemic Sclerosis: Involvement of a Novel Fibrogenic Stromal Cell Subset
Mara Stellato¹, Michal Rudnik¹, Florian Renoux², Elena Pachera¹, Karl Sotlar³, Karin Klingel⁴, Joerg C. Henes⁵, Przemyslaw Blyszczuk⁶, Oliver Distler¹ and Gabriela Kania¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Depertment of Rheumatology, University Hospital Zurich, Schlieren, Switzerland, ³Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁴Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁶Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland
Background/Purpose: Cardiac dysfunction is a significant cause of the high mortality in systemic sclerosis (SSc). Heart involvement in SSc patients resembles inflammatory dilated cardiomyopathy (iDCM)…
Abstract Number: 1845 • 2016 ACR/ARHP Annual Meeting
TGF-β-Induced Tissue Fibrosis Is Abrogated in Mice Containing a Constitutive Genetic Deletion of Nox4 (Nox4 knockout)
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Excessive deposition of collagen and other connective tissue components in the skin and multiple internal organs is characteristic of Systemic Sclerosis (SSc). Besides the…
Abstract Number: 1846 • 2016 ACR/ARHP Annual Meeting
Cutaneous and Visceral Fibrosis Induced By Endothelial Cell-Specific Constitutive Activation of TGF-β1 Signaling in Mice
Peter J. Wermuth, Kellan R. Carney, Fabian A. Mendoza, Sonsoles Piera-Velazquez and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Microvascular damage is an early event in Systemic Sclerosis (SSc) pathogenesis and may represent the initiating stimulus for the subsequent establishment and progression of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].